Not provided
Not provided
Not provided
Not provided
Not provided
Post Market Study terminated early due to the launch and subsequent incorporation of the study into the Terumo Aortic Endovascular Registry (TiGER-001).
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Class |
|---|---|
| Bolton Medical Espana SLU | UNKNOWN |
Not provided
Not provided
Not provided
Not provided
This is an EU sponsored trial and independent of the US trial registered under Clinicaltrials.gov ID NCT02009644.
The purpose of this registry is to gather clinical data on the safety and performance of the TREO Stent-Graft in patients with infrarenal abdominal aortic aneurysms. The registry is part of TREO's EU post-market surveillance plan providing long-term systematic clinical follow-up.
This is a prospective, multicenter, post-market clinical follow-up, non-randomized registry of the TREO Stent-Graft. Subjects diagnosed with infrarenal aortic aneurysms and treated with the TREO Stent-Graft or TREO aorto-uni-iliac (AUI) device can be included into the registry. Pre-procedure baseline data will be gathered as well as post-procedure assessments prior to hospital discharge and one to three months and 1, 2, 3, 4, and 5-year post-implantation.
The objective of the registry is to assess the clinical results and health economics of the TREO device in a real-world population of patients with infrarenal abdominal aortic aneurysms (AAA).
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| TREO Stent-Graft | Experimental | Patients who receive a TREO Abdominal Stent-Graft System |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| TREO Stent-Graft System | Device | The TREO® Stent-Graft is designed for use in the management of patients with AAAs and is composed of self-expanding nitinol stents sutured to polyester vascular graft fabric. |
| Measure | Description | Time Frame |
|---|---|---|
| Aneurysm-related mortality | 30 days post-procedure | |
| Stroke (excluding transient ischemic attack) | 30 days post-procedure | |
| Myocardial infarction | Raised cardiac enzymes within 30 days of the procedure | 30 days post-procedure |
| Renal failure | Renal failure requiring renal replacement therapy (excluding renal insufficiency) | 30 days post-procedure |
| Respiratory failure | excluding chronic obstructive pulmonary disease or pulmonary complications) | 30 days post-procedure |
| Paraplegia | (excluding paraparesis) | 30 days post-procedure |
| Bowel ischemia | A restriction in blood supply to tissues in the bowels | 30 days post-procedure |
| Treated aneurysm rupture | 30 days post-procedure |
| Measure | Description | Time Frame |
|---|---|---|
| Major Adverse Events (MAE) at the follow-up time points | MAE includes any of the following : Aneurysm-related mortality, Stroke (excluding transient ischemic attack), Myocardial infarction, Renal failure requiring renal replacement therapy (excluding renal insufficiency), Respiratory failure (excluding chronic obstructive pulmonary disease or pulmonary complications), Paraplegia (excluding paraparesis), Bowel ischemia, Treated aneurysm rupture |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Giovanni Torsello, MD, PhD | Center of Vascular and Endovascular Surgery, Munster University Hospital | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Imelda Hospital | Bonheiden | 2820 | Belgium | |||
| Imeldaziekenhuis |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
This is a prospective, multi-center, post-market clinical follow-up, non-randomized registry of patients treated with the TREO stent-graft
Not provided
Not provided
Not provided
Not provided
| 30 days post-procedure |
| Limb Ischemia | Rate of clinically-evident ischemia, subcategorized by embolism or thrombosis, tabulated by the frequency of major amputation. | 30 days post-procedure |
| Secondary procedures | Freedom from aneurysm-related secondary procedures through five years follow-up. A questionnaire will be conducted. Investigators are required to conduct a lesion and device assessment at each follow-up visit. All secondary procedures reported will be treated descriptively in terms of results. | 5 years |
| Vascular access complications | Injuries to vessels as a result of the endovascular procedure. | Vascular access will be evaluated on day of index procedure (implant) |
| Patient-reported quality of life (QOL) | Health outcomes using the EuroQol Five Dimensions Questionnaire (EQ-5D) standardized EuroQol instrument. | One year follow-up |
| Bonheiden |
| Belgium |
| AZ Sint Blasius | Dendermonde | Belgium |
| Bonifatius Hospital | Lingen | Germany |
| University Clinic and St. Franziskus Hospital Muenster | Münster | D-48145 | Germany |
| University Hospital Tübingen | Tübingen | Germany |
| Compensorio Sanitario Bolzano | Bolzano | Italy |
| UMC Groningen | Groningen | Netherlands |
| UMCU | Utrecht | Netherlands |
| Hospital Clinic Barcelona | Barcelona | 08036 | Spain |
| Complexo Hospitalario Universitario de Ourense | Ourense | Spain |
| Centro Vascolare Ticino, Ospedale Regionale di Lugano | Lugano | 6903 | Switzerland |
| Civico, Ospedale Regionale | Lugano | Switzerland |
| Addenbrooke's Hospital, Cambridge University Hospitals | Cambridge | United Kingdom |
| Manchester Royal Infirmary, Central Manchester University Hospitals | Manchester | United Kingdom |
| John Radcliffe Hospital, Oxford University Hospitals | Oxford | United Kingdom |
| ID | Term |
|---|---|
| D017544 | Aortic Aneurysm, Abdominal |
| ID | Term |
|---|---|
| D001014 | Aortic Aneurysm |
| D000783 | Aneurysm |
| D014652 | Vascular Diseases |
| D002318 | Cardiovascular Diseases |
| D001018 | Aortic Diseases |
Not provided
Not provided